XL019 / Exelixis - LARVOL DELTA

Xl019, a novel JAK inhibitor, suppressed osteoclasts differentiation induced by RANKL through MAPK signaling pathway. (PubMed, Biochem Pharmacol) - "In addition, titanium particles induced calvarial osteolysis in mice further confirming its beneficial effect on bone homeostasis in vivo. In conclusion, this study demonstrates that Osteoclastactivity canbeeffectivelyinhibitedby XL019viaMAPK signalingpathway,making it a promising alternative pharmacologicaltreatmentfor bone metabolicdisorders."

Journal • Immunology • Metabolic Disorders • Myelofibrosis • Oncology • Osteoporosis • Rheumatology

Hypoxia-induced MIF induces dysregulation of lipid metabolism in Hep2 laryngocarcinoma through the IL-6/JAK-STAT pathway. (PubMed, Lipids Health Dis) - "Hypoxia induced reprogramming of lipid metabolism in laryngocarcinoma cells through the MIF/IL-6/JAK-STAT pathway. This study revealed one mechanism that allows laryngocarcinoma cells to adapt to the hypoxic tumour microenvironment. Therefore, a drug targeting the MIF/IL-6/JAK-STAT pathway might be a promising therapeutic option for the treatment of laryngocarcinoma."

Journal • Laryngeal Cancer • Metabolic Disorders • Oncology • IL6 • LDHA

Drug repurposing for rheumatoid arthritis: Identification of new drug candidates via bioinformatics and text mining analysis. (PubMed, Autoimmunity) - "We hypothesize that the FDA-approved drugs momelotinib, ibrutinib, and sodium butyrate may be promising candidates for RA. In addition, CHEMBL306380, Compound 19a (CHEMBL3116050), ME-344, XL-019, TG100801, JNJ-26483327, and NV-128 were identified as novel repurposing candidates for the treatment of RA. Preclinical and further validation of these drugs may provide new treatment options for RA."

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology